Abstract
Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 194-227 |
| Number of pages | 34 |
| Journal | JNCCN Journal of the National Comprehensive Cancer Network |
| Volume | 13 |
| Issue number | 2 |
| State | Published - Feb 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Esophageal and esophagogastric junction cancers, Version 1.2015. / Ajani, Jaffer A.; D'Amico, Thomas A.; Almhanna, Khaldoun; Bentrem, David J.; Besh, Stephen; Chao, Joseph; Das, Prajnan; Denlinger, Crystal; Fanta, Paul; Fuchs, Charles S.; Gerdes, Hans; Glasgow, Robert E.; Hayman, James A.; Hochwald, Steven; Hofstetter, Wayne L.; Ilson, David H.; Jaroszewski, Dawn; Jasperson, Kory; Keswani, Rajesh N.; Kleinberg, Lawrence R.; Korn, W. Michael; Leong, Stephen; Lockhart, A. Craig; Mulcahy, Mary F.; Orringer, Mark B.; Posey, James A.; Poultsides, George A.; Sasson, Aaron R.; Scott, Walter J.; Strong, Vivian E.; Varghese, Thomas K.; Washington, Mary Kay; Willett, Christopher G.; Wright, Cameron D.; Zelman, Debra; McMillian, Nicole; Sundar, Hema.
In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 13, No. 2, 01.02.2015, p. 194-227.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Esophageal and esophagogastric junction cancers, Version 1.2015
AU - Ajani, Jaffer A.
AU - D'Amico, Thomas A.
AU - Almhanna, Khaldoun
AU - Bentrem, David J.
AU - Besh, Stephen
AU - Chao, Joseph
AU - Das, Prajnan
AU - Denlinger, Crystal
AU - Fanta, Paul
AU - Fuchs, Charles S.
AU - Gerdes, Hans
AU - Glasgow, Robert E.
AU - Hayman, James A.
AU - Hochwald, Steven
AU - Hofstetter, Wayne L.
AU - Ilson, David H.
AU - Jaroszewski, Dawn
AU - Jasperson, Kory
AU - Keswani, Rajesh N.
AU - Kleinberg, Lawrence R.
AU - Korn, W. Michael
AU - Leong, Stephen
AU - Lockhart, A. Craig
AU - Mulcahy, Mary F.
AU - Orringer, Mark B.
AU - Posey, James A.
AU - Poultsides, George A.
AU - Sasson, Aaron R.
AU - Scott, Walter J.
AU - Strong, Vivian E.
AU - Varghese, Thomas K.
AU - Washington, Mary Kay
AU - Willett, Christopher G.
AU - Wright, Cameron D.
AU - Zelman, Debra
AU - McMillian, Nicole
AU - Sundar, Hema
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ.
AB - Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ.
UR - http://www.scopus.com/inward/record.url?scp=84923460712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923460712&partnerID=8YFLogxK
M3 - Article
C2 - 25691612
AN - SCOPUS:84923460712
VL - 13
SP - 194
EP - 227
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
SN - 1540-1405
IS - 2
ER -